|1.||Stea, Baldassarre: 2 articles (07/2008 - 04/2006)|
|2.||Grace, Ana: 1 article (07/2008)|
|3.||Silvain, Daniel: 1 article (07/2008)|
|4.||Stubbs, James: 1 article (07/2008)|
|5.||Chino, Kazumi: 1 article (07/2008)|
|6.||Bastin, Kenneth T: 1 article (04/2006)|
|7.||Burri, Stuart: 1 article (04/2006)|
|8.||Schultz, Christopher: 1 article (04/2006)|
|9.||Patel, Ashish: 1 article (04/2006)|
|10.||Sanan, Abhay: 1 article (04/2006)|
|1.||Brain Neoplasms (Brain Tumor)
07/01/2008 - "Temporary, low dose rate brachytherapy to the margins of resected brain tumors, using a balloon catheter system (GliaSite Radiation Therapy System) and liquid I-125 radiation source (Iotrex), began in 2002 at the University of Arizona Medical Center. "
12/01/2000 - "Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors."
12/01/2000 - "Iotrex is an aqueous radiotherapy solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (125I-HBS), which is used as the radiation source for the brachytherapy of resected of brain tumor cavity margins with the GliaSite catheter. "
04/01/2006 - "The balloon was afterloaded with liquid I (Iotrex) to deliver a median dose of 60 Gy to an average depth of 1 cm with a median dose rate of 52.3 Gy/hr. Patients were carefully followed with serial magnetic resonance imaging and monthly examinations for tumor progression, side effects, and survival. "